A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Adv…

Inclusion Criteria: The main inclusion criteria include but are not limited to the following:
*  Has a histologically confirmed diagnosis of locally advanced unresectable or metastatic (unresectable Stage III or Stage IV as defined by American Joint Committee on Cancer \[AJCC\] eighth edition) colorectal adenocarcinoma
*  Part 2 only: Has not received systemic anticancer therapy for locally advanced unresectable or metastatic colorectal cancer
*  Tumor tissue demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
*  Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
*  Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load
*  Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable

Exclusion Criteria: The main exclusion criteria include but are not limited to the following:
*  Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, chronic diarrhea)
*  Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
*  Has known dihydropyrimidine dehydrogenase (DPD) deficiency
*  HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
*  Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization
*  Has 1 or more conditions that, in the opinion of the investigator, make the participant ineligible for treatment with bevacizumab
*  Has known additional malignancy that is progressing or has required active treatment within the past 3 years
*  Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease
*  Has active infection requiring systemic therapy
*  Has not adequately recovered from major surgery or have ongoing surgical complications
*  Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease